The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial

Cremer, 1994, Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS), Eur J Clin Invest, 24, 444, 10.1111/j.1365-2362.1994.tb02373.x Danesh, 2000, Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies, Circulation, 102, 1082, 10.1161/01.CIR.102.10.1082 Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 Bambauer, 1997, Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results, Ther Dial, 1, 242 Bohl, 2009, Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by Stress/Rest perfusion magnetic resonance imaging, Ther Dial, 13, 129, 10.1111/j.1744-9987.2009.00667.x 2013, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment, Eur Heart J, 34, 1279, 10.1093/eurheartj/eht055 Borberg, 2009, Comparison of different Lp(a) elimination techniques: a retrospective evaluation, TransApheresSci, 41, 61 Merki, 2011, Antisense oligonucleotide lowers plasma levels of apolipoprotein(a) and lipoprotein (a) in transgenic mice, J Am Coll Cardiol, 57, 1611, 10.1016/j.jacc.2010.10.052 Thompson, 2010, Severe hypercholesterolaemia; therapeutic goals and eligibility criteria for LDL apheresis in Europe, Curr Opin Lipidol, 21, 492, 10.1097/MOL.0b013e3283402f53 Kim, 2002, Refractory angina pectoris. Mechanism and therapeutic options, J Am Coll Cardiol, 39, 923, 10.1016/S0735-1097(02)01716-3 Mannheimer, 2002, The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina, Eur Heart J, 23, 355, 10.1053/euhj.2001.2706 Ibrahim, 2012, Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease, J Clin Lipidol, 6, 192, 10.1016/j.jacl.2011.11.003 Leebmann, 2013, Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease. Prospective observational multicenter study, Circulation, 128, 2567, 10.1161/CIRCULATIONAHA.113.002432 Jaeger, 2009, Longitudinal cohort study on the effectiveness of apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events, Nat Clin Pract Cardiovasc Med, 6, 229, 10.1038/ncpcardio1456 Safarova, 2013, Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography, Atheroscler Suppl, 14, 93, 10.1016/j.atherosclerosissup.2012.10.015 Saraf, 2010, Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction, JACC, 55, 2107, 10.1016/j.jacc.2010.01.033